Hi All,
Has anyone had a poke at estimating NPAT for FY17 given that EBITDA should be in the order of $5M?
And has R&D already been written off and proved for in the EBITDA estimate? Or is that a post EBITDA phase of accounting?
Gosouth
Ann: ITL Trading Update, page-13
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
